Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?
Publication

Publications

Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?

Title
Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?
Type
Another Publication in an International Scientific Journal
Year
2020-08-13
Authors
Paulo Linhares
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Journal
Vol. 21 No. 7
Pages: 1-16
ISSN: 1661-6596
Publisher: MDPI
Other information
Authenticus ID: P-00S-MNP
Abstract (EN): Glioblastoma (GBM) is the most frequent malignant primary brain tumor in adults, characterized by a highly aggressive, inflammatory and angiogenic phenotype. It is a remarkably heterogeneous tumor at several levels, including histopathologically, radiographically and genetically. The 2016 update of the WHO Classification of Tumours of the Central Nervous System highlighted molecular parameters as paramount features for the diagnosis, namelyIDH1/2mutations that distinguish primary and secondary GBM. An ideal biomarker is a molecule that can be detected/quantified through simple non- or minimally invasive methods with the potential to assess cancer risk; promote early diagnosis; increase grading accuracy; and monitor disease evolution and treatment response, as well as fundamentally being restricted to one aspect. Blood-based biomarkers are particularly attractive due to their easy access and have been widely used for various cancer types. A number of serum biomarkers with multiple utilities for glioma have been reported that could classify glioma grades more precisely and provide prognostic value among these patients. At present, screening for gliomas has no clinical relevance. This is because of the low incidence, the lack of sensitive biomarkers in plasma, and the observation that gliomas may develop apparently de novo within few weeks or months. To the best of our knowledge, there is no routine use of a serum biomarker for clinical follow-up. The purpose of this paper is to review the serum biomarkers described in the literature related to glioblastoma and their possible relationship with clinical features.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 16
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

The importance of the neutrophil-to-lymphocyte ratio in the prognosis of glioma and its subtypes (2020)
Another Publication in an International Scientific Journal
Paulo Linhares
Early deep brain stimulation in patients with myoclonus-dystonia syndrome (2016)
Another Publication in an International Scientific Journal
Paulo Linhares
Survival Determinants in Glioblastoma: An Insight into Biopsy-Only Patient Outcomes (2024)
Other Publications
Gonçalves, JM; Ferreira, F; Carvalho, B; Polónia, P; Linhares, P
Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients (2024)
Other Publications
Gonçalves, JM; Carvalho, B; Tuna, R; Polónia, P; Linhares, P
Quantitative and qualitative long-term mortality analysis in Parkinson's disease treated with deep brain stimulation (2013)
Other Publications
Rocha, S; Gomes, J; Monteiro, A; Linhares, P; Chamadoira, C; Ayres Basto, MA; Reis, C; Sousa, C; Lima, J; Rosas, MJ; Massano, J; Vaz, R

See all (45)

Of the same journal

Vanadium Compounds with Antidiabetic Potential (2023)
Another Publication in an International Scientific Journal
Amaral, LMPF; Moniz, T; Silva, AMN; Maria Rangel
Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis (2019)
Another Publication in an International Scientific Journal
Ferreira, N; Maria Joao Saraiva; Almeida, MR
Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems (2019)
Another Publication in an International Scientific Journal
Souto, EB; Dias Ferreira, J; Oliveira, J; Sanchez Lopez, E; Lopez Machado, A; Espina, M; Garcia, ML; Souto, SB; Martins Gomes, C; Silva, AM
Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review (2024)
Another Publication in an International Scientific Journal
Coimbra, S; Rocha, S; Sousa, NR; Cristina Catarino; Belo, L; Bronze da Rocha, E; Valente, MJ; Santos-Silva, A
Therapeutic Approaches for Age-Related Macular Degeneration (2022)
Another Publication in an International Scientific Journal
Galindo-Camacho, RM; Blanco-Llamero, C; da Ana, R; Fuertes, MA; Senorans, FJ; Silva, AM; Garcia, ML; Souto, EB

See all (282)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-17 at 04:18:29 | Privacy Policy | Personal Data Protection Policy | Whistleblowing